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Objectives
There is a need for techniques to conduct Clinical Trials
(CTs) in Alzheimer’s Disease (AD) and Mild Cognitive
Impairment (MCI) more efficiently to reduce their dura-
tion and cost. However, large variability in the rating
scales increases the number of subjects required to
obtain significant results in the CTs [1,2]. Alternatively,
Magnetic Resonance Imaging (MRI) and Cerebrospinal
Fluid (CSF) are promising AD biomarkers but none is
optimal for all disease stages [1,2]. Additionally,
Machine Learning can detect biomarker patterns to
characterize AD and MCI. In this study, we assessed the
usefulness of Machine Learning to select subjects with
the clearest signs of the disease for inclusion in more
efficient CTs [3,4].
Methods
We tested three Machine Learning classifiers: Logistic
Regression (LR), Support Vector Machine (SVM) and
Radial Basis Function (RBF) [4]. These techniques were
trained to recognise disease patterns in 91 AD, 178 MCI
and 106 cognitive normal (CN) subjects from ADNI [1]
for whom baseline age, MRI hippocampal volume, MRI
entorhinal cortical thickness, CSF Ab42 and CSF phos-
pho-Tau181p levels were measured. From the classifiers,
we obtained a likelihood value that each subject was AD
or MCI and not CN. Then, the patients with higher
likelihood (i.e., clearer signs) of the disease were first
selected for inclusion in hypothetical CTs. This
approach was evaluated in the terms of reduction in the
number of patients needed in the CTs to detect a 25%
reduction in the hippocampal volume after one year
(80% power, two-sided test, p-value=0.05) [3,4].
Results
Without the selection of subjects based on the classi-
fiers, the hypothetical CTs required 109 patients for AD
and 183 subjects for MCI per group (treatment vs. pla-
cebo). In contrast, the sample sizes decreased consider-
ably when the classifiers based on the biomarkers were
used to select one third of the subjects with the highest
likelihood (clearest signs) of the disease, as shown in
Table 1. All these group sizes were at least eight times
smaller than those estimated when ADAS-cog, instead
of the hippocampus, was the outcome measure in the
CT (Table 2).
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Table 1 Minimum number of subjects required per arm
for a hypothetical CT with the hippocampal volume as
outcome measure in AD and MCI. Two cases are
considered: when all subjects are included in the CT, and
when only the 33% of the subjects with the clearest
signs of AD are selected for the CT.
Condition Subset LR SVM RBF
AD All subjects 109 109 109
33% of subjects with the clearest signs of
AD
48 93 30
MCI All subjects 183 183 183
33% of subjects with the clearest signs of
AD
95 139 104
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The results highlighted the potential of CSF and MRI
biomarkers and Machine Learning classifiers (particu-
larly LR and RBF) as objective tools to select subjects
for more efficient CTs in AD and MCI. However,
further analyses are needed to corroborate these results
and extend this approach to other biomarkers and
classifiers.
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Table 2 Minimum number of subjects required per arm
for a hypothetical CT with the ADAS-cog as outcome
measure in AD and MCI. Two cases are considered: when
all subjects are included in the CT, and when only the
33% of the subjects with the clearest signs of AD are
selected for the CT.
Condition Selection LR SVM RBF
AD All subjects 1330 1330 1330
33% of subjects with the clearest signs
of AD
1675 1605 259
MCI All subjects 8878 8878 8878
33% of subjects with the clearest signs
of AD
3098 1148 2119
Escudero et al. Trials 2011, 12(Suppl 1):A18
http://www.trialsjournal.com/content/12/S1/A18
Page 2 of 2